No Data
No Data
Express News | Brainstorm Cell Therapeutics Inc Says on July 18, Co Received Mvls Deficiency Notice From the Listing Qualifications Department Staff of Nasdaq
Maxim Group Upgrades Brainstorm Cell Therapeutics(BCLI.US) to Buy Rating, Announces Target Price $2
Maxim Group analyst Jason McCarthy upgrades $Brainstorm Cell Therapeutics(BCLI.US)$ to a buy rating, and sets the target price at $2.According to TipRanks data, the analyst has a success rate of 24.0%
Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial
Brainstorm Cell Therptcs Price Target Announced at $2.00/Share by Maxim Group
Brainstorm Cell Therptcs Price Target Announced at $2.00/Share by Maxim
Express News | Maxim Group Upgrades Brainstorm Cell to Buy, Announces $2 Price Target
Brainstorm Cell Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 455.56% Maxim Group → $2 Upgrades Hold → Buy 09/28/2023 — Maxim Group Downgrades Buy → Hold 03
FattyChick : If this hits $2, im a millionaire.![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)